Snake venom-derived peptide MQ232 shows promise as kidney-targeted treatment for hyponatremia and polycystic kidney disease | Research

The takeaway

MQ232, a reticulated peptide optimized from snake toxin, showed low toxicity, strong kidney accumulation, pure aquaretic effect, and improved kidney cyst pathology in polycystic kidney disease mouse models.

Kidney-targeted aquaretic
Snake venom peptide MQ232 selectively accumulates in kidneys and removes water without electrolyte loss—addressing a key limitation of current diuretics

What the researchers found

MQ232: low acute/chronic toxicity. Strong kidney biodistribution. Pure aquaretic effect (water only, no electrolytes). Improved kidney histology in PKD mouse model. Derived from snake toxin with disulfide-bond reticulation.

Why it matters

Hyponatremia affects millions of hospitalized patients and PKD has no cure. A kidney-targeted peptide that removes water without electrolyte loss addresses a critical therapeutic gap.

How the study worked

Peptide optimization from snake toxin. Toxicology in rats. Biodistribution in mice. Aquaretic efficacy assessment. PKD mouse model histology.

What this study cannot tell us

Preclinical only. PKD model results are histological, not functional. Human pharmacokinetics unknown. Manufacturing of disulfide-bonded peptides can be challenging.

How to read the evidence

Preclinical with toxicology, biodistribution, and disease model data. Good drug development package.

When this study was published

Published in 2025.

The bigger picture

Venom-derived peptides continue to yield drug candidates (ziconotide from cone snails, exenatide from Gila monster). MQ232 adds to this tradition with a kidney-targeted application.

Questions still open

Would MQ232 outperform tolvaptan for PKD?
Can it treat SIADH-associated hyponatremia?
Is the peptide stable enough for clinical development?

Common questions

Can snake venom treat kidney disease?

A peptide derived from snake venom (MQ232) was engineered to target the kidneys specifically. In animal studies, it safely removed excess water without losing essential electrolytes and improved kidney cyst disease. This represents a new approach to treating conditions where the body retains too much water.

How does MQ232 differ from regular diuretics?

Most diuretics remove both water and electrolytes (sodium, potassium), which can cause dangerous imbalances. MQ232 produces "aquaresis"—removing only water. This makes it potentially safer for treating low sodium (hyponatremia) and fluid retention without causing electrolyte problems.

Read the original research

A Snake Toxin Derivative for Treatment of Hyponatremia and Polycystic Kidney Diseases.

Journal of the American Society of Nephrology : JASN, 36(2), 181-192

View on PubMed ↗Publisher’s paper ↗

Citation

Stanajic-Petrovic, Goran; Keck, Mathilde; Barbe, Peggy; Urman, Apolline; Correia, Evelyne; Isnard, Pierre; Duong Van Huyen, Jean-Paul; Chmeis, Khawla; Diarra, Sékou Siramakan; Palea, Stefano; Theodoro, Frederic; Nguyen, Anvi-Laëtitia; Castelli, Florence; Pruvost, Alain; Zhao, Wenchao; Mendre, Christiane; Mouillac, Bernard; Bienaimé, Frank; Robin, Philippe; Kessler, Pascal; Llorens-Cortes, Catherine; Servent, Denis; Nozach, Hervé; Maillère, Bernard; Guo, Dong; Truillet, Charles; Gilles, Nicolas. (2025). A Snake Toxin Derivative for Treatment of Hyponatremia and Polycystic Kidney Diseases.. Journal of the American Society of Nephrology : JASN, 36(2), 181-192. https://doi.org/10.1681/ASN.0000000505